{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:53:56Z","timestamp":1777870436149,"version":"3.51.4"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Deceased donor kidneys are a scarce national resource, and principles of utilitarianism and justice govern allocation. Kidney transplant recipients with a prior history of cancer show an increased risk of malignancy- and non-malignancy-related mortality compared to their counterparts without a previous history of malignancy. The inferior survival of a recipient with pre-transplant malignancy questions the allocation of a scarce resource to a population at anticipated poorer patient\u00a0and\u00a0graft survival. However, patient survival has significantly improved with advances in therapeutics for hematological malignancies, which led to an updated consensus expert opinion by the American Society of Transplantation in 2019. Nevertheless, the candidacy of patients with pre-transplant hematological malignancies in countries with a scarcity of deceased donor kidneys and a prolonged wait time may warrant specific considerations. This review details the basis for evaluation and candidacy recommendations for patients with a history of hematological malignancy for waitlist placement for deceased donor kidney transplantation, while optimizing scarce deceased donor organ supply in \u00a0Singapore. It considers the available evidence in countries where organ scarcity is a distinct challenge; thus, this consensus report is tailored to these constraints and may not be fully generalizable to other countries or transplant allocation algorithms.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s40620-025-02381-8","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T06:35:40Z","timestamp":1755844540000},"page":"2041-2052","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Deceased donor kidney transplantation in candidates with pre-transplant hematological malignancies: a literature review and recipient allocation proposal\u00a0in Singapore"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5831-8420","authenticated-orcid":false,"given":"Emmett Tsz Yeung","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3777-706X","authenticated-orcid":false,"given":"Ian Tatt","family":"Liew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1056-083X","authenticated-orcid":false,"given":"Hein","family":"Than","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1299-8560","authenticated-orcid":false,"given":"Aloysius Yew Leng","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-2226","authenticated-orcid":false,"given":"Chandramouli","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7069-0997","authenticated-orcid":false,"given":"Yeow Tee","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0834-9333","authenticated-orcid":false,"given":"Charles Thuan Heng","family":"Chuah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8854-9414","authenticated-orcid":false,"given":"Michelle Limei","family":"Poon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-8335","authenticated-orcid":false,"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7392-0655","authenticated-orcid":false,"given":"Melissa Gaik Ming","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8881-3537","authenticated-orcid":false,"given":"Widanalage Sanjay Prasad","family":"De Mel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6454-976X","authenticated-orcid":false,"given":"Allen Eng Juh","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5250-855X","authenticated-orcid":false,"given":"Terence","family":"Kee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6701-412X","authenticated-orcid":false,"given":"Anantharaman","family":"Vathsala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"2381_CR1","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1093\/ndt\/gfz026","volume":"34","author":"B Watschinger","year":"2019","unstructured":"Watschinger B, Budde K, Crespo M et al (2019) Pre-existing malignancies in renal transplant candidates\u2014time to reconsider waiting times. Nephrol Dial Transplant 34:1292\u20131300. https:\/\/doi.org\/10.1093\/ndt\/gfz026","journal-title":"Nephrol Dial Transplant"},{"key":"2381_CR2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/tp.0000000000001192","volume":"101","author":"SA Acuna","year":"2017","unstructured":"Acuna SA, Huang JW, Daly C et al (2017) Outcomes of solid organ transplant recipients with preexisting malignancies in remission. Transplantation 101:471\u2013481. https:\/\/doi.org\/10.1097\/tp.0000000000001192","journal-title":"Transplantation"},{"key":"2381_CR3","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/tp.0000000000003136","volume":"104","author":"SJ Chadban","year":"2020","unstructured":"Chadban SJ, Ahn C, Axelrod DA et al (2020) Kdigo clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Transplantation 104:S11\u2013S103. https:\/\/doi.org\/10.1097\/tp.0000000000003136","journal-title":"Transplantation"},{"key":"2381_CR4","volume-title":"2022 USRDS annual data report: epidemiology of kidney disease in the United States","author":"USRD System","year":"2022","unstructured":"System USRD (2022) 2022 USRDS annual data report: epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD"},{"key":"2381_CR5","unstructured":"(2023) National Organ Transplant Unit, Singapore."},{"key":"2381_CR6","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.34067\/kid.0002472021","volume":"2","author":"JH Wang","year":"2021","unstructured":"Wang JH, Hart A (2021) Global perspective on kidney transplantation: United States. Kidney360 2:1836\u20131839. https:\/\/doi.org\/10.34067\/kid.0002472021","journal-title":"Kidney360"},{"key":"2381_CR7","unstructured":"Singapore M of H Facts about Organ Donation. https:\/\/www.liveon.gov.sg\/facts.html. Accessed 5 Jul 2024"},{"key":"2381_CR8","unstructured":"Transplant NB and Organ Transplantation: How long is the wait for a kidney? https:\/\/www.nhsbt.nhs.uk\/organ-transplantation\/kidney\/receiving-a-kidney\/how-long-is-the-wait-for-a-kidney\/. Accessed 5 Jul 2024"},{"key":"2381_CR9","unstructured":"Registry A 44th Report, Chapter 6: Australian Transplant Waiting List. Adelaide, Australia"},{"key":"2381_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/ajt.16318","volume":"21","author":"DP Al-Adra","year":"2021","unstructured":"Al-Adra DP, Hammel L, Roberts J et al (2021) Pretransplant solid organ malignancy and organ transplant candidacy: a consensus expert opinion statement. Am J Transplant 21:460\u2013474. https:\/\/doi.org\/10.1111\/ajt.16318","journal-title":"Am J Transplant"},{"key":"2381_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/ajt.16324","volume":"21","author":"DP Al-Adra","year":"2021","unstructured":"Al-Adra DP, Hammel L, Roberts J et al (2021) Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: a consensus expert opinion statement. Am J Transplant 21:475\u2013483. https:\/\/doi.org\/10.1111\/ajt.16324","journal-title":"Am J Transplant"},{"key":"2381_CR12","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.mayocp.2016.09.010","volume":"91","author":"S Paul","year":"2016","unstructured":"Paul S, Kantarjian H, Jabbour EJ (2016) Adult acute lymphoblastic leukemia. Mayo Clin Proc 91:1645\u20131666. https:\/\/doi.org\/10.1016\/j.mayocp.2016.09.010","journal-title":"Mayo Clin Proc"},{"key":"2381_CR13","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M (2017) Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 7:e577\u2013e577. https:\/\/doi.org\/10.1038\/bcj.2017.53","journal-title":"Blood Cancer J"},{"key":"2381_CR14","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/s0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M (2020) Acute lymphoblastic leukaemia. Lancet 395:1146\u20131162. https:\/\/doi.org\/10.1016\/s0140-6736(19)33018-1","journal-title":"Lancet"},{"key":"2381_CR15","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","volume":"19","author":"PA Brown","year":"2021","unstructured":"Brown PA, Shah B, Advani A et al (2021) Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19:1079\u20131109. https:\/\/doi.org\/10.6004\/jnccn.2021.0042","journal-title":"J Natl Compr Canc Netw"},{"key":"2381_CR16","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1002\/cncr.29383","volume":"121","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, O\u2019Brien S, Konopleva M, Kantarjian H (2015) New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer 121:2517\u20132528. https:\/\/doi.org\/10.1002\/cncr.29383","journal-title":"Cancer"},{"key":"2381_CR17","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1200\/jco.2011.40.5936","volume":"30","author":"AEJ Yeoh","year":"2012","unstructured":"Yeoh AEJ, Ariffin H, Chai ELL et al (2012) Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol 30:2384\u20132392. https:\/\/doi.org\/10.1200\/jco.2011.40.5936","journal-title":"J Clin Oncol"},{"key":"2381_CR18","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","volume":"120","author":"F Locatelli","year":"2012","unstructured":"Locatelli F, Schrappe M, Bernardo ME, Rutella S (2012) How i treat relapsed childhood acute lymphoblastic leukemia. Blood 120:2807\u20132816. https:\/\/doi.org\/10.1182\/blood-2012-02-265884","journal-title":"Blood"},{"key":"2381_CR19","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1034\/j.1399-0012.1999.130409.x","volume":"13","author":"JA Butcher","year":"1999","unstructured":"Butcher JA, Hariharan S, Adams MB et al (1999) Renal transplantation for end-stage renal disease following bone marrow transplantation: a report of six cases, with and without immunosuppression. Clin Transplant 13:330\u2013335. https:\/\/doi.org\/10.1034\/j.1399-0012.1999.130409.x","journal-title":"Clin Transplant"},{"key":"2381_CR20","doi-asserted-by":"publisher","first-page":"E94","DOI":"10.1111\/j.1399-0012.2009.01155.x","volume":"24","author":"A Beitinjaneh","year":"2010","unstructured":"Beitinjaneh A, Burns LJ, Majhail NS (2010) Solid organ transplantation in survivors of hematopoietic cell transplantation: a single institution case series and literature review. Clin Transplant 24:E94\u2013E102. https:\/\/doi.org\/10.1111\/j.1399-0012.2009.01155.x","journal-title":"Clin Transplant"},{"key":"2381_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10157-018-1672-1","volume":"23","author":"A Tsuchimoto","year":"2019","unstructured":"Tsuchimoto A, Masutani K, Omoto K et al (2019) Kidney transplantation for treatment of end-stage kidney disease after haematopoietic stem cell transplantation: case series and literature review. Clin Exp Nephrol 23:561\u2013568. https:\/\/doi.org\/10.1007\/s10157-018-1672-1","journal-title":"Clin Exp Nephrol"},{"key":"2381_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5301\/jo-n.5000022","volume":"1","author":"A Sethi","year":"2017","unstructured":"Sethi A, Rhodes J, Mato A, Hogan JJ (2017) Chronic lymphocytic leukemia and the kidney. J Onco-Nephrol 1:103\u2013109. https:\/\/doi.org\/10.5301\/jo-n.5000022","journal-title":"J Onco-Nephrol"},{"key":"2381_CR23","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/j.cmonc.2012.09.019","volume":"9","author":"LJ Nastoupil","year":"2012","unstructured":"Nastoupil LJ, Flowers CR (2012) Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice. Community Oncol 9:S85\u2013S92. https:\/\/doi.org\/10.1016\/j.cmonc.2012.09.019","journal-title":"Community Oncol"},{"key":"2381_CR24","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1111\/j.1600-6143.2008.02383.x","volume":"8","author":"G D\u2019Ythurbide","year":"2008","unstructured":"D\u2019Ythurbide G, Coppo P, Adem A et al (2008) Chronic lymphocytic leukemia: a hazardous condition before kidney transplantation. Am J Transplant 8:2471\u20132475. https:\/\/doi.org\/10.1111\/j.1600-6143.2008.02383.x","journal-title":"Am J Transplant"},{"key":"2381_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/bjh.13759","volume":"174","author":"P Strati","year":"2016","unstructured":"Strati P, Gharaibeh KA, Leung N et al (2016) Solid organ transplant in individuals with monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia. Br J Haematol 174:162\u2013165. https:\/\/doi.org\/10.1111\/bjh.13759","journal-title":"Br J Haematol"},{"key":"2381_CR26","unstructured":"Nazmul M, Miles CD, Chiluru VK, et al (2017). Successful kidney transplantation and chronic lymphocytic leukemia: a case report. In: American society of nephrology kidney week"},{"key":"2381_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1046\/j.1525-139x.1999.99021.x","volume":"12","author":"I Penn","year":"1999","unstructured":"Penn I (1999) Acceptance criteria for transplantation in patients with malignancies. Semin Dial 12:207\u2013208. https:\/\/doi.org\/10.1046\/j.1525-139x.1999.99021.x","journal-title":"Semin Dial"},{"key":"2381_CR28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/ajt.14970","volume":"19","author":"M Eder","year":"2019","unstructured":"Eder M, Schwarz C, Kammer M et al (2019) Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor\u2014a multicenter analysis. Am J Transplant 19:475\u2013487. https:\/\/doi.org\/10.1111\/ajt.14970","journal-title":"Am J Transplant"},{"key":"2381_CR29","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/10428194.2018.1461863","volume":"60","author":"H Than","year":"2019","unstructured":"Than H, Lye WK, Sng C et al (2019) BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients. Leuk Lymphoma 60:234\u2013237. https:\/\/doi.org\/10.1080\/10428194.2018.1461863","journal-title":"Leuk Lymphoma"},{"key":"2381_CR30","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/leu.2015.73","volume":"29","author":"VS Hoffmann","year":"2015","unstructured":"Hoffmann VS, Baccarani M, Hasford J et al (2015) The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries. Leukemia 29:1336\u20131343. https:\/\/doi.org\/10.1038\/leu.2015.73","journal-title":"Leukemia"},{"key":"2381_CR31","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"key":"2381_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.lrr.2013.02.003","volume":"2","author":"S Martino","year":"2013","unstructured":"Martino S, Daguindau E, Ferrand C et al (2013) A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib. Leuk Res Rep 2:29\u201331. https:\/\/doi.org\/10.1016\/j.lrr.2013.02.003","journal-title":"Leuk Res Rep"},{"key":"2381_CR33","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.transproceed.2019.10.035","volume":"52","author":"K Shinoda","year":"2020","unstructured":"Shinoda K, Morita S, Tamaki S et al (2020) Successful treatment of end-stage renal disease in a patient with chronic myeloid leukemia by kidney transplantation and tyrosine kinase inhibitors: a case report. Transplant Proc 52:604\u2013607. https:\/\/doi.org\/10.1016\/j.transproceed.2019.10.035","journal-title":"Transplant Proc"},{"key":"2381_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/ajt.16194","volume":"21","author":"U Thiem","year":"2021","unstructured":"Thiem U, Buxhofer-Ausch V, Kranewitter W et al (2021) Successful kidney transplantation in a patient with pre-existing chronic myeloid leukemia treated with imatinib. Am J Transplant 21:405\u2013409. https:\/\/doi.org\/10.1111\/ajt.16194","journal-title":"Am J Transplant"},{"key":"2381_CR35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"2381_CR36","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/jco.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133067. https:\/\/doi.org\/10.1200\/jco.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"2381_CR37","unstructured":"UK CR (2023) Hodgkin lymphoma statistics. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/hodgkin-lymphoma#:~:text=Hodgkin%20lymphoma%20survival&text=More%20than%209%20in%2010,50%20years%20in%20the%20UK. Accessed 21 Aug 2023"},{"key":"2381_CR38","unstructured":"Society AC (2023). Survival Rates for Hodgkin Lymphoma. Accessed 21 Aug 2023"},{"key":"2381_CR39","unstructured":"Institute NC, Program SR SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. https:\/\/seer.cancer.gov\/explorer\/. Accessed 23 Oct 2023"},{"key":"2381_CR40","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3390\/medicina57101026","volume":"57","author":"O Potre","year":"2021","unstructured":"Potre O, Pescaru M, Sima A et al (2021) Evaluation of the relapse risk and survival rate in patients with Hodgkin lymphoma: a monocentric experience. Medicina (Kaunas) 57:1026. https:\/\/doi.org\/10.3390\/medicina57101026","journal-title":"Medicina (Kaunas)"},{"key":"2381_CR41","first-page":"21","volume":"8","author":"A Ahmadzadeh","year":"2014","unstructured":"Ahmadzadeh A, Yekaninejad MS, Jalili MH et al (2014) Evaluating the survival rate and the secondary malignancies after treating Hodgkin\u2019s lymphoma patients with chemotherapy regimens. Int J Hematol-Oncol stem cell Res 8:21\u201326","journal-title":"Int J Hematol-Oncol stem cell Res"},{"key":"2381_CR42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1601-0825.2009.01586.x","volume":"16","author":"E Zapater","year":"2010","unstructured":"Zapater E, Bag\u00e1n J, Carbonell F, Basterra J (2010) Malignant lymphoma of the head and neck. Oral Dis 16:119\u2013128. https:\/\/doi.org\/10.1111\/j.1601-0825.2009.01586.x","journal-title":"Oral Dis"},{"key":"2381_CR43","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Neste EVD et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the groupe d\u2019etudes des lymphomes de l\u2019adulte. Blood 116:2040\u20132045. https:\/\/doi.org\/10.1182\/blood-2010-03-276246","journal-title":"Blood"},{"key":"2381_CR44","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/nejmoa2115304","volume":"386","author":"H Tilly","year":"2021","unstructured":"Tilly H, Morschhauser F, Sehn LH et al (2021) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386:351\u2013363. https:\/\/doi.org\/10.1056\/nejmoa2115304","journal-title":"N Engl J Med"},{"key":"2381_CR45","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1200\/jco.19.00014","volume":"37","author":"Y Wang","year":"2019","unstructured":"Wang Y, Farooq U, Link BK et al (2019) Late relapses in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 37:1819\u20131827. https:\/\/doi.org\/10.1200\/jco.19.00014","journal-title":"J Clin Oncol"},{"key":"2381_CR46","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M et al (2007) The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857\u20131861. https:\/\/doi.org\/10.1182\/blood-2006-08-038257","journal-title":"Blood"},{"key":"2381_CR47","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/jco.19.01073","volume":"37","author":"E Bachy","year":"2019","unstructured":"Bachy E, Seymour JF, Feugier P et al (2019) Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol 37:2815\u20132824. https:\/\/doi.org\/10.1200\/jco.19.01073","journal-title":"J Clin Oncol"},{"key":"2381_CR48","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjh.14241","volume":"175","author":"CW Eskelund","year":"2016","unstructured":"Eskelund CW, Kolstad A, Jerkeman M et al (2016) 15-year follow-up of the second Nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol 175:410\u2013418. https:\/\/doi.org\/10.1111\/bjh.14241","journal-title":"Br J Haematol"},{"key":"2381_CR49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a057673","volume":"1","author":"B Coiffier","year":"1990","unstructured":"Coiffier B, Brousse N, Peuchmaur M et al (1990) Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Ann Oncol 1:45\u201350. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a057673","journal-title":"Ann Oncol"},{"key":"2381_CR50","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1097\/01.tp.0000140845.10630.4f","volume":"78","author":"J Trofe","year":"2004","unstructured":"Trofe J, Buell JF, Woodle ES et al (2004) Recurrence risk after organ transplantation in patients with a history of Hodgkin disease or non-Hodgkin lymphoma. Transplantation 78:972\u2013977. https:\/\/doi.org\/10.1097\/01.tp.0000140845.10630.4f","journal-title":"Transplantation"},{"key":"2381_CR51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/jop.2017.028480","volume":"14","author":"PJ Bierman","year":"2018","unstructured":"Bierman PJ (2018) Solid organ transplantation in patients with a history of lymphoma. J Oncol Pract 14:11\u201317. https:\/\/doi.org\/10.1200\/jop.2017.028480","journal-title":"J Oncol Pract"},{"key":"2381_CR52","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/ndt\/gfaa361","volume":"37","author":"DW Chitty","year":"2020","unstructured":"Chitty DW, Hartley-Brown MA, Abate M et al (2020) Kidney transplantation in patients with multiple myeloma: narrative analysis and review of the last two decades. Nephrol Dial Transplant 37:1616\u20131626. https:\/\/doi.org\/10.1093\/ndt\/gfaa361","journal-title":"Nephrol Dial Transplant"},{"key":"2381_CR53","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/nejmoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, Therneau TM, Rajkumar SV et al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564\u2013569. https:\/\/doi.org\/10.1056\/nejmoa01133202","journal-title":"N Engl J Med"},{"key":"2381_CR54","doi-asserted-by":"publisher","first-page":"e723","DOI":"10.1097\/txd.0000000000001176","volume":"7","author":"N Aslam","year":"2021","unstructured":"Aslam N, Trautman CL, Sher T (2021) Kidney transplantation and monoclonal gammopathy of undetermined significance. Transplant Direct 7:e723. https:\/\/doi.org\/10.1097\/txd.0000000000001176","journal-title":"Transplant Direct"},{"key":"2381_CR55","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3727\/096368915x688560","volume":"25","author":"O Baraldi","year":"2016","unstructured":"Baraldi O, Grandinetti V, Donati G et al (2016) Hematopoietic cell and renal transplantation in plasma cell dyscrasia patients. Cell Transplant 25:995\u20131005. https:\/\/doi.org\/10.3727\/096368915x688560","journal-title":"Cell Transplant"},{"key":"2381_CR56","first-page":"243","volume":"77","author":"K Amaador","year":"2019","unstructured":"Amaador K, Peeters H, Minnema MC et al (2019) Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options. Neth J Med 77:243\u2013254","journal-title":"Neth J Med"},{"key":"2381_CR57","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/ki.2015.201","volume":"88","author":"C Cohen","year":"2015","unstructured":"Cohen C, Royer B, Javaugue V et al (2015) Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int 88:1135\u20131143. https:\/\/doi.org\/10.1038\/ki.2015.201","journal-title":"Kidney Int"},{"key":"2381_CR58","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/ki.2008.577","volume":"75","author":"PG Czarnecki","year":"2009","unstructured":"Czarnecki PG, Lager DJ, Leung N et al (2009) Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits. Kidney Int 75:420\u2013427. https:\/\/doi.org\/10.1038\/ki.2008.577","journal-title":"Kidney Int"},{"key":"2381_CR59","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1053\/j.ajkd.2021.04.015","volume":"79","author":"C Heybeli","year":"2022","unstructured":"Heybeli C, Alexander MP, Bentall AJ et al (2022) Kidney transplantation in patients with monoclonal gammopathy of renal significance (MGRS)\u2013associated lesions: a case series. Am J Kidney Dis 79:202\u2013216. https:\/\/doi.org\/10.1053\/j.ajkd.2021.04.015","journal-title":"Am J Kidney Dis"},{"key":"2381_CR60","doi-asserted-by":"publisher","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","volume":"25","author":"H Ludwig","year":"2020","unstructured":"Ludwig H, Durie SN, Meckl A et al (2020) Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist 25:e1406\u2013e1413. https:\/\/doi.org\/10.1634\/theoncologist.2020-0141","journal-title":"Oncologist"},{"key":"2381_CR61","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","volume":"18","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Callander NS, Adekola K et al (2020) Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 18:1685\u20131717. https:\/\/doi.org\/10.6004\/jnccn.2020.0057","journal-title":"J Natl Compr Canc Netw"},{"key":"2381_CR62","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97:1086\u20131107. https:\/\/doi.org\/10.1002\/ajh.26590","journal-title":"Am J Hematol"},{"key":"2381_CR63","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14541","volume":"36","author":"AR Dinh","year":"2022","unstructured":"Dinh AR, Wong SW, Martin TG et al (2022) Outcomes of kidney transplant recipients with ESKD due to plasma cell dyscrasia: a case series. Clin Transplant 36:e14541. https:\/\/doi.org\/10.1111\/ctr.14541","journal-title":"Clin Transplant"},{"key":"2381_CR64","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.ekir.2022.01.003","volume":"7","author":"C Heybeli","year":"2022","unstructured":"Heybeli C, Bentall AJ, Alexander MP et al (2022) Kidney transplant outcomes of patients with multiple myeloma. Kidney Int Rep 7:752\u2013762. https:\/\/doi.org\/10.1016\/j.ekir.2022.01.003","journal-title":"Kidney Int Rep"},{"key":"2381_CR65","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1053\/j.ajkd.2016.12.023","volume":"69","author":"TX Le","year":"2017","unstructured":"Le TX, Wolf JL, Peralta CA, Webber AB (2017) Kidney transplantation for kidney failure due to multiple myeloma: case reports. Am J Kidney Dis 69:858\u2013862. https:\/\/doi.org\/10.1053\/j.ajkd.2016.12.023","journal-title":"Am J Kidney Dis"},{"key":"2381_CR66","doi-asserted-by":"publisher","DOI":"10.1097\/txd.0000000000000716","volume":"3","author":"EL Lum","year":"2017","unstructured":"Lum EL, Kogut N, Pham T et al (2017) Kidney transplantation in patients with active multiple myeloma. Transplant Direct 3:e200. https:\/\/doi.org\/10.1097\/txd.0000000000000716","journal-title":"Transplant Direct"},{"key":"2381_CR67","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13023-022-02414-6","volume":"17","author":"N Kumar","year":"2022","unstructured":"Kumar N, Zhang NJ, Cherepanov D et al (2022) Global epidemiology of amyloid light-chain amyloidosis. Orphanet J Rare Dis 17:278. https:\/\/doi.org\/10.1186\/s13023-022-02414-6","journal-title":"Orphanet J Rare Dis"},{"key":"2381_CR68","doi-asserted-by":"publisher","first-page":"67","DOI":"10.6004\/jnccn.2023.0001","volume":"21","author":"SK Kumar","year":"2023","unstructured":"Kumar SK, Callander NS, Adekola K et al (2023) Systemic light chain amyloidosis, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw\u202f: JNCCN 21:67\u201381. https:\/\/doi.org\/10.6004\/jnccn.2023.0001","journal-title":"J Natl Compr Cancer Netw : JNCCN"},{"key":"2381_CR69","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1111\/j.1600-6143.2010.03227.x","volume":"10","author":"PT Sattianayagam","year":"2010","unstructured":"Sattianayagam PT, Gibbs SDJ, Pinney JH et al (2010) Solid organ transplantation in AL amyloidosis. Am J Transplant 10:2124\u20132131. https:\/\/doi.org\/10.1111\/j.1600-6143.2010.03227.x","journal-title":"Am J Transplant"},{"key":"2381_CR70","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1093\/ndt\/gfr067","volume":"26","author":"SMS Herrmann","year":"2011","unstructured":"Herrmann SMS, Gertz MA, Stegall MD et al (2011) Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant 26:2032\u20132036. https:\/\/doi.org\/10.1093\/ndt\/gfr067","journal-title":"Nephrol Dial Transplant"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02381-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-025-02381-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02381-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:59:26Z","timestamp":1777564766000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/8\/2041\/8457493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":70,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["2381"],"URL":"https:\/\/doi.org\/10.1007\/s40620-025-02381-8","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"15 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a literature review and consensus report. No ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No human subjects were involved. Informed consent was thus not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent to participate"}}]}}